A Meta-Analysis of Neurodevelopmental Outcomes following Intravitreal Bevacizumab for the Treatment of Retinopathy of Prematurity.

ABSTRACT:

Background

Retinopathy of prematurity (ROP) is the most common cause of preventable blindness in preterm infants. First-line treatments include intravitreal bevacizumab (IVB) or laser photocoagulation (LPC).

Objectives

The aim of the study was to evaluate neurodevelopmental safety of IVB compared to LPC for ROP.

Methods

MEDLINE, Embase, and Cochrane library were searched up to September 2022. Studies were included with at least 12-month follow-up of primary outcomes such as severe neurodevelopmental impairment (sNDI), cerebral palsy (CP), and hearing impairment (HI). Secondary outcomes were moderate-to-severe neurodevelopmental impairment (msNDI), Bayley Scores of Infant Development (BSID-III), and visual impairment.

Results

1,231 patients from 11 comparative s

SUBMITTER: Baiad AA 

PROVIDER: S-EPMC10777715 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature